Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $166
Canaccord Genuity analyst Whitney Ijem maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $180 to $166.
Stocks · News reference
8-K filing — Neurogene Inc. (NGNE)
Filed: 2026-08-11 AccNo: 0001404644-26-000056 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81
Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $65
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $70 to $65.
Neurogene Q2 EPS $(1.53) Misses $(1.39) Estimate
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.39) by 10.07 percent. This is a 45.71 percent decrease over losses of $(1.05) per share from the